PCRSG Bio – Dr. Janusz Skowronek

Assistant Professor, Head of Brachytherapy
Greater Poland Cancer Center, Poznań, Poland

Janusz Skowronek, MD, PhD, is Associate Professor of Radiation Oncology at Poznań University of Medical Sciences and Head of the Brachytherapy Department at the Greater Poland Cancer Center in Poznań, Poland.

In 1984, Dr. Skowronek started his education at the Medical Academy in Poznań, faculty of Medicine, where he received his MD and was awarded a medal for “Great Achievement in Study and Community Service” in 1990. In June 1996 he received his PhD at the Medical Academy in Poznań, and he received his Assistant Professor Degree at the Medical Academy in Poznań in 2006. Dr.

Skowronek has worked at the Greater Poland Cancer Center since 1990, where he was Head of the General Brachytherapy Laboratory since 2003 and Head of the Brachytherapy Department since 2005. In addition, he has worked as the Associate Professor of the Electroradiology Department at the Poznań University of Medical Sciences since 2012.



In addition to lecturing extensively both nationally and internationally, Dr. Skowronek established and directs the Journal of Contemporary Brachytherapy, a journal entirely devoted to brachytherapy, and is a member of many other editorial boards. He has published more than 100 manuscripts and book chapters, is a member of the Groupe Européen de Curiethérapie (GEC)-European Society for Radiotherapy and Oncology Committee and UROGEC group, vice president of the Polish Brachytherapy Society, chairman of the Polish Oncological Society (Branch of Poznań), and an active member of the American Brachytherapy Society, American Society for Radiation Oncology, and other societies.



In the past 20 years, his research has focused exclusively on radiotherapy, particularly the implementation of interstitial high-dose rate (HDR) and low-dose rate (LDR) (as first center in Poland) brachytherapy of prostate cancer, development of a modern method of pulsed dose rate (PDR) brachytherapy in different types of malignant tumors, introduction of brachytherapy of coronary artery restenosis and peripheral artery restenosis, HDR/PDR brachytherapy of bile duct cancers, and HDR/PDR brachytherapy of head and neck cancers.